Journal of Addiction Medicine最新文献

{"title":"Fetal Fentanyl Syndrome: An Opportunity to Quantify the Risk in Prospective Cohorts of Patients With Substance Use Disorder.","authors":"Sonia Hernandez-Diaz, Krista F Huybrechts","doi":"10.1097/ADM.0000000000001676","DOIUrl":"10.1097/ADM.0000000000001676","url":null,"abstract":"<p><p>The increased availability of fentanyl in the United States over the past decade extends to women of reproductive age, raising concern about maternal and fetal risks when used in pregnancy. A 2023 case series of 10 infants exposed to fentanyl in utero proposed a \"fetal fentanyl syndrome\" (FFS), characterized by distinctive craniofacial features, limb anomalies, and genitourinary defects. However, as with any case series, concerns about selective case ascertainment, uncontrolled confounding, imprecise timing of exposure, phenotype heterogeneity, and lack of a denominator preclude causal inference or risk quantification. Two new studies in this issue-Mirsky et al and Dorsey et al-had the opportunity to quantify the risk in prospective cohorts of patients with substance use disorder. However, they leave key questions unresolved. Mirsky et al identify 4 additional infants with craniofacial anomalies and prenatal fentanyl exposure, but their analysis remains effectively a case series. Dorsey et al use a case-control analysis and report a modestly elevated odds of FFS-compatible anomalies with fentanyl exposure, but broad exposure windows, limited phenotype specificity, and lack of adjustment for confounding limit interpretability. Further studies are needed to clarify to what extent prenatal fentanyl exposure contributes to specific patterns of congenital structural anomalies.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e1-e3"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147485852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Butorphanol-induced Precipitated Opioid Withdrawal With Stress Cardiomyopathy in the Setting of Chronic Fentanyl Use.","authors":"Oyeyimika Oyekanmi, Hannah Kissel-Smith, Monica N Melmer, Brandon Wills","doi":"10.1097/ADM.0000000000001567","DOIUrl":"10.1097/ADM.0000000000001567","url":null,"abstract":"<p><strong>Background: </strong>Precipitated opioid withdrawal due to partial opioid agonists other than buprenorphine is rarely reported. We present a case of severe precipitated opioid withdrawal and stress cardiomyopathy after butorphanol use in the setting of chronic fentanyl use.</p><p><strong>Case summary: </strong>Emergency medical services responded to a 61-year-old female with opioid use disorder (OUD) who was severely agitated requiring multiple doses of sedatives. Emergency department examination was notable for extreme agitation and restlessness. An electrocardiogram showed sinus tachycardia without ischemic changes. Urine drug immunoassay was positive for benzodiazepines and fentanyl, despite no fentanyl administration by providers. A transthoracic echocardiogram showed evidence of stress cardiomyopathy. A subsequent comprehensive urine drug analysis was positive for norfentanyl and butorphanol. The patient confirmed using butorphanol immediately before the onset of symptoms. The patient's goals were to resume treatment of OUD with buprenorphine. She stabilized on buprenorphine 16 mg/4 mg sublingual film daily, then transitioned to buprenorphine long-acting injectable 96 mg subcutaneous monthly.</p><p><strong>Discussion: </strong>Butorphanol is a synthetic partial agonist at the μ-opioid receptor and full agonist at the κ-opioid receptor. It is available in several formulations and is frequently used as a veterinary analgesic. Precipitated opioid withdrawal from butorphanol has been demonstrated in experimental settings but has not been described in clinical practice.</p><p><strong>Conclusions: </strong>This case emphasizes the importance of recognizing butorphanol as a partial opioid agonist capable of causing precipitated opioid withdrawal in the setting of chronic opioid agonist exposure, and underscores potential medical consequences of precipitated opioid withdrawal including stress cardiomyopathy.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"516-518"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Newly Filled GLP-1 Receptor Agonist Prescriptions for US Patients With Versus Without Comorbid Alcohol Use Disorder, 2016-2024.","authors":"Joshua D Wallach, Stephanie S O'Malley, Kasia J Lipska, Joseph S Ross, Molly M Jeffery, Samuel T Savitz","doi":"10.1097/ADM.0000000000001575","DOIUrl":"10.1097/ADM.0000000000001575","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate trends in newly filled GLP-1 receptor agonist (GLP-1RA) prescriptions among U.S. adults with type 2 diabetes (T2DM) and/or obesity, comparing those with and without comorbid alcohol use disorder (AUD), and to assess differences in their demographic and clinical characteristics.</p><p><strong>Methods: </strong>We used national claims data from Optum Labs Data Warehouse, which includes de-identified administrative and pharmacy claims from commercially insured and Medicare Advantage (MA) enrollees throughout the U.S., to identify adults who newly filled GLP-1RA-based prescriptions between April 1, 2016, and March 31, 2024. We calculated quarterly rates of new GLP-1RA fills per 100 person-years and compared the characteristics of individuals with T2DM and/or obesity with and without comorbid AUD.</p><p><strong>Results: </strong>From 2016 to 2024, 555,224 individuals with T2DM and/or obesity newly filled prescriptions for GLP-1RAs, of whom 6606 had comorbid AUD. The rate of new GLP-1RA fills for individuals with comorbid AUD increased from 1.27 to 6.02 per 100 person-years between 2016-2024 [incident rate ratio (IRR): 4.73 (95% CI 3.38, 6.79)], compared with an increase of 2.21 to 6.55 per 100 person-years among individuals without comorbid AUD [IRR: 2.96 (95% CI 2.88, 3.05)]. Individuals with AUD were more likely to be MA enrollees under age 65, male, have had a recent emergency department visit, and have co-occurring psychiatric and medical conditions compared with those without comorbid AUD.</p><p><strong>Conclusions: </strong>From 2016 to 2024, the rate of newly filled GLP-1RA prescriptions increased among individuals with T2DM and/or obesity and comorbid AUD. Individuals with comorbid AUD were more likely to be male and to have clinical characteristics linked to greater AUD severity. Additional clinical studies on the efficacy and safety of GLP-1RAs for AUD are needed to guide their appropriate use.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"472-479"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12636227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145206468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Validity of International Classification of Diseases Codes for Identifying Alcohol Use and Repeated or Harm-associated Alcohol Use in Pregnancy.","authors":"Paulina M Devlin, Zoe Riggs, Elizabeth Charron, Salman Yakub, Katherine A Sward, Julie Shakib, Vasee Sivaloganathan, Marcela C Smid","doi":"10.1097/ADM.0000000000001579","DOIUrl":"10.1097/ADM.0000000000001579","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the validity of alcohol use disorder (AUD), the International Classification of Diseases (ICD) codes for alcohol use and repeated or harm-associated use in pregnancy.</p><p><strong>Methods: </strong>We conducted a retrospective study of pregnancies in individuals who sought care at a medical center from May 2014 to August 2023. We selected all pregnancies with an ICD 9th (ICD-9) or 10th (ICD-10) revision AUD code (ICD-9: 303.9x and 305.x; ICD-10: F10.x and O99.31x) and calculated their positive predictive value (PPV) for capturing alcohol use and repeated or harm-associated use in pregnancy using review of health record as the reference standard. We defined alcohol use as any alcohol consumption during pregnancy and repeated or harm-associated alcohol use as a repeated pattern associated with adverse consequences.</p><p><strong>Results: </strong>AUD ICD codes were associated with 305 unique pregnancies. The most common AUD ICD code group was 305.x (n=177, 56.4%), followed by F10.x (n=105, 33.4%), O99.31x (n=25, 8.0%), and 303.9x (n=7, 2.2%). The PPV of AUD codes for capturing alcohol use in pregnancy ranged from 10.0% (95% confidence interval [CI], 8.9%-11.2%) for 305.x to 100% (95% CI, 80.9%-99.5%) for O99.31x. The PPV of AUD codes for capturing repeated or harm-associated use in pregnancy ranged from 1.7% (95% CI, 1.6%-1.8%) for 305.x to 28.0% (95% CI, 21.3%-35.9%) for O99.31x.</p><p><strong>Conclusions: </strong>The PPV of AUD codes for identifying alcohol use and repeated or harm-associated use in pregnancy varies widely across ICD-9 and ICD-10 code groups. These results should be considered when estimating alcohol exposure in pregnancy from administrative data.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"498-503"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145069646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DSM-5 Stimulant Use Disorder Severity, Stimulant Craving, and Other Clinical Characteristics Based on Stimulant Type (Cocaine, Methamphetamine, Nonmedical Prescription Stimulants, or Polystimulants).","authors":"Joshua Truchan, Ty S Schepis, Emily Pasman, Vita V McCabe, Sean Esteban McCabe","doi":"10.1097/ADM.0000000000001563","DOIUrl":"10.1097/ADM.0000000000001563","url":null,"abstract":"<p><strong>Objectives: </strong>This study examined DSM-5 stimulant use disorder (StimUD) symptom severity, stimulant craving, and clinical characteristics associated with different stimulant types.</p><p><strong>Methods: </strong>Nationally representative cross-sectional data from the 2021-2022 National Survey on Drug Use and Health (N = 117,103) was analyzed to determine the past-year prevalence and adjusted odds of DSM-5 StimUD symptom severity, stimulant craving, psychological distress, suicidality, and major depressive episodes among individuals who used crack cocaine, methamphetamine, non-crack cocaine, nonmedical prescription stimulants (NPSU), or polystimulants (≥2 stimulants).</p><p><strong>Results: </strong>Past-year DSM-5 StimUD was most prevalent and severe among individuals who used crack cocaine, methamphetamine-only, or polystimulants, versus non-crack cocaine-only and NPSU-only. Stimulant craving was the most prevalent DSM-5 StimUD symptom, highest among those reporting polystimulant use (56.6%), followed by methamphetamine-only (51.2%), crack cocaine (48.0%), non-crack cocaine-only (18.6%), and NPSU-only (16.6%). Stimulant craving showed a dose-response association with more frequent use. Polystimulant use was associated with the highest rates of psychological distress, suicidal ideation, suicide attempt, and major depressive episodes. In controlled analyses, adjusted odds of impaired control, social impairment, risky use, pharmacologic indicators, and craving were greater among those using crack cocaine, methamphetamine-only, and polystimulants, relative to NPSU-only. Individuals reporting non-crack cocaine use-only had lower odds of psychological distress [AOR = 0.63 (95% CI = 0.44-0.92)] and major depressive episodes [AOR = 0.61 (95% CI = 0.40-0.91)] compared with NPSU-only.</p><p><strong>Conclusions: </strong>Individuals using different stimulant types differ in DSM-5 StimUD symptoms, craving, and other clinical characteristics, especially those engaged in crack cocaine, methamphetamine, and polystimulant use. Health care professionals should consider these differences when treating individuals who use stimulants.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"428-436"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12890082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144954862","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Opioid Use Disorder Screening Practices in US Jails.","authors":"Amanda M Bunting, Sami Sobh, Wen-Yu Lee, Matthew Lee, David Farabee","doi":"10.1097/ADM.0000000000001570","DOIUrl":"10.1097/ADM.0000000000001570","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the screening processes for opioid use disorder by jails in localities with high concentrations of opioid involved overdose deaths.</p><p><strong>Methods: </strong>A secondary data analysis of structured interviews on opioid use disorder practices from 185 jails in the United States was conducted. Descriptive statistics detailed jail screening characteristics, and bivariate statistics examined the association between screening characteristics and annual jail population.</p><p><strong>Results: </strong>The majority of jails in high-overdose-burden localities had screening protocols in place for opioid use disorder (95.1%). The protocols varied, with most jails reporting the use of substance use (85.4%) or opioid use (77.0%) specific screeners. Yet few jails used validated screening tools (23.3%) and instead relied on agency or state-specific tools (89.0%). Significant differences by annual jail population were found related to who conducted screenings, such that the use of medical staff for screening ( P <0.01) and clinical assessments ( P <0.05) was more likely among larger jails.</p><p><strong>Conclusions: </strong>Screening and assessment of opioid use disorder is essential for individuals in jails, given the disproportionate burden of the disorder. Jails tended to rely on agency-created tools over the use of validated screeners, and more efforts may be needed to close the research-practice divide.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"508-510"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855282","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Polymicrobial Pathogens From Licking Syringe Plungers: A Case Report and Artificial-intelligence-augmented Scoping Review of Oropharyngeal Bacterial Infections Linked to Unsafe Injection Practices.","authors":"Molly M Perri, Cara Borelli, Alyssa Cheng","doi":"10.1097/ADM.0000000000001574","DOIUrl":"10.1097/ADM.0000000000001574","url":null,"abstract":"<p><strong>Objectives: </strong>People who inject drugs are at an increased risk of infectious complications. Certain injection practices can lead to bacterial complications from oral flora, including licking needles or using saliva to clean the skin. We report the first case in the literature of a patient licking the syringe plunger and present a scoping review to identify other injection practices associated with oropharyngeal bacterial complications from injecting drugs.</p><p><strong>Methods: </strong>The authors searched OVID Medline, Embase, and APA PsycINFO to identify case reports and case series of patients with infections related to salivary contamination in the injection process. Studies with suspected unsafe injection practices based on the pathogen, but with no specific injection practices reported, were excluded. Artificial intelligence (AI) was utilized to augment the traditional scoping review by refining search criteria for a repeated traditional search and conducting iterative AI literature searches using embedded links.</p><p><strong>Results: </strong>Nine sources were identified with AI-augmented embedded article searching that were not identified in the traditional scoping review. One source was identified with AI-augmented search criteria. If only the traditional scoping review had been used, 3 of the 13 articles would have been identified.</p><p><strong>Conclusions: </strong>The scoping review identified unexpected etiologies of oropharyngeal bacterial contamination, not limited to licking needles, illustrating the importance of gaining an in-depth, step-by-step understanding of how each patient with intravenous drug use injects to identify potential modes of infection. This case also provides an example of potential advancements in artificial intelligence to augment research by improving search strategies, such as MeSH terms and identifying articles.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"467-471"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145329231","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descriptive Exploration of Features Among Infants With Prenatal Fentanyl Exposure in a Multisite Cohort of Maternal-Infant Dyads Affected by Opioid Use Disorder.","authors":"Amanda N Dorsey, Sonja A Rasmussen, Janet D Cragan, Shin Y Kim, Pilar M Sanjuan, Tanner Wright, Claire Williams, Kate Woodworth, Marcela C Smid, Mishka Terplan, Neil S Seligman, Shawn A Thomas, Thomas G O'Connor, Elisha Wachman, Lawrence M Leeman, Michelle L Henninger, Kristen L Benninger, Kara M Rood, Julie H Shakib, Autumn Davidson, Amy Board","doi":"10.1097/ADM.0000000000001650","DOIUrl":"10.1097/ADM.0000000000001650","url":null,"abstract":"<p><strong>Objectives: </strong>A recent case series suggested a possible syndrome associated with prenatal fentanyl exposure. We described, among a cohort of maternal-infant dyads affected by opioid use disorder (OUD), the prevalence of these observed infant features.</p><p><strong>Methods: </strong>We used data from MAT-LINK, a surveillance system compiling electronic health record (EHR) information from 7 US clinical sites on pregnancies affected by OUD between 2014 and 2021. We described the prevalence of EHR-documented prenatal fentanyl exposure and infant features of interest (cleft palate, corpus callosum abnormality, foot positioning deformities, genital anomalies, microcephaly, micrognathia, toe syndactyly).</p><p><strong>Results: </strong>Among 5053 maternal-infant dyads affected by OUD, 667 (13.5%; 95% CI: 13.0%-14.0%) had documented prenatal fentanyl exposure, including an over 20-fold increase from 2014 to 2021. Health insurance, prenatal care timing, and nonopioid substance exposures differed between dyads with and without documented prenatal fentanyl exposure. At least one feature of interest was documented for 406 (8.0%) infants, and at least 2 were documented for 0.7%. Among infants with at least one of these features, 18.9% (95% CI: 17.1%-20.8%) had documented prenatal fentanyl exposure, compared with 13.0% (95% CI: 12.5%-13.6%) of infants without any of these features.</p><p><strong>Conclusions: </strong>In this perinatal OUD cohort, prenatal fentanyl exposure was more commonly documented among infants with at least one compared with none of these infant features. However, features were rare and contextual factors differed among dyads by prenatal fentanyl exposure status. Further analyses examining these infant features, while considering multiple exposures, are needed before substantiating a fetal fentanyl syndrome.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"e4-e11"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13316998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145966307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence and Stigma in Addiction Research: Insights From the HEALing Communities Study Coalition Meetings.","authors":"Nabila El-Bassel, James L David, Eric Aragundi, Scott T Walters, Elwin Wu, Louisa Gilbert, Redonna Chandler, Tim Hunt, Victoria Frye, Aimee N C Campbell, Dawn A Goddard-Eckrich, Marc Chen, Parixit Davé, Shoshana N Benjamin, David Lounsbury, Nasim Sabounchi, Maneesha Aggarwal, Dan Feaster, Terry Huang, Tian Zheng","doi":"10.1097/ADM.0000000000001749","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001749","url":null,"abstract":"","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":"20 4","pages":"e15"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148678618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacokinetic Interactions Between Ethanol and PT150, a Selective Glucocorticoid Receptor Antagonist, in Healthy Volunteers.","authors":"Adetola Vaughan, Cassius K Mensah, Jenny Pennycuff, Sandy S Venneman, Victoria Risborough, Dewleen G Baker, Kayla J Nowak, Rick L Williams, Tracy L Nolen, Thomas R Kosten, Christopher D Verrico","doi":"10.1097/ADM.0000000000001557","DOIUrl":"10.1097/ADM.0000000000001557","url":null,"abstract":"<p><strong>Objectives: </strong>PT150, a novel competitive glucocorticoid receptor antagonist, is hypothesized to be a potential treatment for alcohol use disorder, with safety studies as an important first step for medication development. We aimed to assess PT150 safety and tolerability, including impact on pharmacokinetics when administered concomitantly with ethanol in healthy participants.</p><p><strong>Methods: </strong>This nonrandomized, single-site, drug-drug interaction study of PT150, coadministered with oral ethanol (alcohol beverage), was conducted at the Michael E. DeBakey Veterans Affairs Medical Center in Houston, TX. Participants, each of whom received the same exposure sequence and served as their own control, were healthy, alcohol-experienced volunteers aged 21-64 years. Blood samples were obtained before and after 1.03 mL/kg ethanol exposure, before and after the fifth dose of PT150 (900 mg/d), and again before and after a sixth dose of PT150 (900 mg/d) administered with 1.03 mL/kg of ethanol. The primary pharmacokinetic outcomes included differences in peak plasma concentrations ( Cmax ), time to reach peak plasma concentrations ( tmax ), terminal elimination half-life ( t1/2 ), and area under the concentration-time curve (AUC) of PT150 alone and in combination with ethanol.</p><p><strong>Results: </strong>There was no statistically significant evidence that coexposure to ethanol impacted PT150 pharmacokinetics, and no statistically significant evidence that coexposure to PT150 impacted ethanol pharmacokinetics. There were no clinically significant abnormal electrocardiograms or serious adverse events.</p><p><strong>Conclusions: </strong>These data suggest that coadministration of PT150 and alcohol does not produce significant pharmacokinetic interactions, supporting the feasibility of evaluating PT150 in future clinical trials for alcohol use disorder.</p>","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":"409-415"},"PeriodicalIF":3.1,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}